Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States?

In the quest for "evidence-based" medicine, an accepted hierarchy of evidence has been proposed. This hierarchy places in vitro studies and animal data at the base, and puts systematic reviews, meta-analyses, and randomized controlled trials at the pinnacle. However, when clinical medicine...

Full description

Saved in:
Bibliographic Details
Published inCurrent hypertension reports Vol. 8; no. 3; pp. 219 - 225
Main Author Hawkins, Ralph G
Format Journal Article
LanguageEnglish
Published United States Springer Nature B.V 01.06.2006
Subjects
Animals
Clinical trials
Diuretics - adverse effects
Hypertension
Hypertension - drug therapy
Hypertension - epidemiology
Incidence
Kidney Failure, Chronic - chemically induced
Kidney Failure, Chronic - epidemiology
Medical research
Population Surveillance
United States - epidemiology
United States
Online AccessGet full text

Cover

More Information
Summary:In the quest for "evidence-based" medicine, an accepted hierarchy of evidence has been proposed. This hierarchy places in vitro studies and animal data at the base, and puts systematic reviews, meta-analyses, and randomized controlled trials at the pinnacle. However, when clinical medicine faces questions that have not yet been studied by the "gold standard" methods, how is one to proceed? Often, the best evidence at hand falls short of randomized controlled trials and meta-analyses. Using this framework, a review of the evidence supporting the hypothesis that population-wide diuretic use is directly associated with end-stage renal disease in the United States is presented. Publications pertaining to diuretic use in recent clinical trials are also discussed.
ISSN:1522-6417
1534-3111
DOI:10.1007/s11906-006-0054-3